SCHEMBL5465629

SCHEMBL5465629

COc1ccc(COC(=O)c2cc(C=C3SC(=O)N(Cc4ccc(-c5ccccc5)cc4)C3=O)ccc2O)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.56
ACP1 P24666 8/20 0.56
HPGD P15428 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
KDM4E B2RXH2 1/20 0.55
ALPL P05186 1/20 0.55
MAPT P10636 1/20 0.55
MAPK1 P28482 1/20 0.55
RECQL P46063 1/20 0.55
ENPP2 Q13822 7/20 0.55
PTPN2 P17706 4/20 0.54
PTPRF P10586 2/20 0.53
PTPRB P23467 2/20 0.53
HSD17B3 P37058 1/20 0.52
PPARG P37231 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465627 1.00 PTPN1 (0.56) PTPN1ACP1HPGDMEN1KMT2A
SCHEMBL5470526 0.88 PIM1 (0.55) PTPN1ACP1HPGDMEN1KMT2A
SCHEMBL5470531 0.88 PIM1 (0.55) PTPN1ACP1HPGDMEN1KMT2A
SCHEMBL5464405 0.87 ENPP2 (0.70) PTPN1ACP1ENPP2PTPN2PTPRF
SCHEMBL5464400 0.87 ENPP2 (0.70) PTPN1ACP1ENPP2PTPN2PTPRF
SCHEMBL5462991 0.83 PTPN1 (0.65) PTPN1ACP1MEN1KMT2AENPP2
SCHEMBL5462986 0.83 PTPN1 (0.65) PTPN1ACP1MEN1KMT2AENPP2
SCHEMBL12177684 0.83 ENPP2 (0.67) PTPN1ACP1KDM4EMAPTMAPK1
SCHEMBL5455135 0.83 MAPK1 (0.59) PTPN1ACP1MEN1KMT2AMAPT
SCHEMBL5455133 0.83 MAPK1 (0.59) PTPN1ACP1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 PTPN1 3264/4885ACP1 254/4885HPGD 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.